Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Operating Income history
Currency unavailable · from the income statement
No Operating Income data reported for this period type.
Operating Income vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$46.86M USD | — | — | — |
| LTM Mar 2026 | -$66.69M USD | -29.4% | — | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$66.85M USD | -256.5% | — | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$122.21M USD | -31.3% | — | 611.0% |
| LTM Mar 2026 | -$160.36M USD | -111.1% | — | 73.6% | |
| LTM Mar 2026 | -$210.04M USD | -140.9% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$223.08M USD | +18.7% | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -71.2% | — | 342.3% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.